{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:17:33Z","timestamp":1787872653580,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44492-7","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:14:28Z","timestamp":1778757268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of empagliflozin on inflammation and oxidative stress in patients undergoing percutaneous coronary intervention, a randomized controlled trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Susan","family":"Darroudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Ghazaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Babaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab Sadat","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Jamili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Ensan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazale","family":"Donyadide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pagnoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Coppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed Hashemi","family":"Shahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Moohebati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"44492_CR1","doi-asserted-by":"crossref","unstructured":"Doll, J. A. et al. Management of Percutaneous Coronary Intervention Complications: Algorithms From the 2018 and 2019 Seattle Percutaneous Coronary Intervention Complications Conference. Circ Cardiovasc Interv. (6):e008962. (2020).","DOI":"10.1161\/CIRCINTERVENTIONS.120.008962"},{"issue":"10","key":"44492_CR2","doi-asserted-by":"publisher","first-page":"e025729","DOI":"10.1161\/JAHA.122.025729","volume":"11","author":"R Mohebi","year":"2022","unstructured":"Mohebi, R. et al. A Biomarker-Enhanced Model for Prediction of Acute Kidney Injury and Cardiovascular Risk Following Angiographic Procedures: CASABLANCA AKI Prediction Substudy. J. Am. Heart Assoc. 11 (10), e025729 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"44492_CR3","doi-asserted-by":"publisher","first-page":"108801","DOI":"10.1016\/j.pharmthera.2025.108801","volume":"267","author":"Z Wang","year":"2025","unstructured":"Wang, Z. et al. From physiology to pathology: Emerging roles of GPER in cardiovascular disease. Pharmacol. Ther. 267, 108801 (2025).","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"44492_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4330\/wjc.v10.i9.74","volume":"10","author":"J Gonz\u00e1lez-Montero","year":"2018","unstructured":"Gonz\u00e1lez-Montero, J., Brito, R., Gajardo, A. I. & Rodrigo, R. Myocardial reperfusion injury and oxidative stress: Therapeutic opportunities. World J. Cardiol. 10 (9), 74 (2018).","journal-title":"World J. Cardiol."},{"issue":"1","key":"44492_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12967-020-02574-8","volume":"18","author":"P Kusirisin","year":"2020","unstructured":"Kusirisin, P., Chattipakorn, S. C. & Chattipakorn, N. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. J. Transl Med. 18 (1), 400 (2020).","journal-title":"J. Transl Med."},{"issue":"5","key":"44492_CR6","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1007\/s10753-025-02289-2","volume":"48","author":"X Wang","year":"2025","unstructured":"Wang, X., Xie, N., Zhang, H., Zhou, W. & Lei, J. Isoorientin Ameliorates Macrophage Pyroptosis and Atherogenesis by Reducing KDM4A Levels and Promoting SKP1-Cullin1-F-box E3 Ligase-mediated NLRP3 Ubiquitination. Inflammation 48 (5), 3629\u20133648 (2025).","journal-title":"Inflammation"},{"key":"44492_CR7","first-page":"1","volume":"2020","author":"MH Bao","year":"2020","unstructured":"Bao, M. H. et al. A Novel Putative Role of TNK1 in Atherosclerotic Inflammation Implicating the Tyk2\/STAT1 Pathway. Mediators Inflamm. 2020, 1\u20139 (2020).","journal-title":"Mediators Inflamm."},{"issue":"5","key":"44492_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/j.1445-5994.2011.02500.x","volume":"42","author":"AA Evangelopoulos","year":"2012","unstructured":"Evangelopoulos, A. A. et al. Association between serum cystatin C, monocytes and other inflammatory markers. Intern. Med. J. 42 (5), 517\u2013522 (2012).","journal-title":"Intern. Med. J."},{"issue":"12","key":"44492_CR9","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.amjmed.2005.07.060","volume":"118","author":"MG Shlipak","year":"2005","unstructured":"Shlipak, M. G. et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am. J. Med. 118 (12), 1416\u2013e25 (2005).","journal-title":"Am. J. Med."},{"key":"44492_CR10","doi-asserted-by":"crossref","unstructured":"Hu, Y. et al. GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. Eur. Heart J. ;ehaf1066. (2026).","DOI":"10.1093\/eurheartj\/ehaf1066"},{"key":"44492_CR11","doi-asserted-by":"publisher","first-page":"154918","DOI":"10.1016\/j.metabol.2021.154918","volume":"126","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism 126, 154918 (2022).","journal-title":"Metabolism"},{"issue":"6746","key":"44492_CR12","doi-asserted-by":"publisher","first-page":"eado4188","DOI":"10.1126\/science.ado4188","volume":"388","author":"H Lin","year":"2025","unstructured":"Lin, H. et al. Metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis. Science 388 (6746), eado4188 (2025).","journal-title":"Science"},{"issue":"4","key":"44492_CR13","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/ijms26041670","volume":"26","author":"EY Rykova","year":"2025","unstructured":"Rykova, E. Y. et al. Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages. Int. J. Mol. Sci. 26 (4), 1670 (2025).","journal-title":"Int. J. Mol. Sci."},{"issue":"3\u20134","key":"44492_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.clinbiochem.2006.10.017","volume":"40","author":"DH Alamdari","year":"2007","unstructured":"Alamdari, D. H. et al. A novel assay for the evaluation of the prooxidant\u2013antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin. Biochem. 40 (3\u20134), 248\u2013254 (2007).","journal-title":"Clin. Biochem."},{"issue":"4","key":"44492_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/cvr\/cvq138","volume":"87","author":"L Xie","year":"2010","unstructured":"Xie, L. et al. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc. Res. 87 (4), 628\u2013635 (2010).","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"44492_CR16","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1038\/s41598-024-82991-7","volume":"15","author":"ZS Hosseini","year":"2025","unstructured":"Hosseini, Z. S. et al. Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial. Sci. Rep. 15 (1), 3940 (2025).","journal-title":"Sci. Rep."},{"key":"44492_CR17","doi-asserted-by":"publisher","first-page":"104870","DOI":"10.1016\/j.phrs.2020.104870","volume":"158","author":"CN Koyani","year":"2020","unstructured":"Koyani, C. N. et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol. Res. 158, 104870 (2020).","journal-title":"Pharmacol. Res."},{"key":"44492_CR18","doi-asserted-by":"crossref","unstructured":"Wang, W. et al. hua, yan,. A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis. Acta Pharmacol Sin. ;45(10):2119\u201333. (2024).","DOI":"10.1038\/s41401-024-01305-9"},{"key":"44492_CR19","doi-asserted-by":"publisher","first-page":"112515","DOI":"10.1016\/j.biopha.2021.112515","volume":"146","author":"L Uthman","year":"2022","unstructured":"Uthman, L. et al. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na+] c\/ROS-pathway in human endothelial cells. Biomed. Pharmacother. 146, 112515 (2022).","journal-title":"Biomed. Pharmacother"},{"key":"44492_CR20","doi-asserted-by":"publisher","first-page":"879522","DOI":"10.3389\/fmolb.2022.879522","volume":"9","author":"S Giannattasio","year":"2022","unstructured":"Giannattasio, S. et al. Cell-target-specific anti-inflammatory effect of empagliflozin: In vitro evidence in human cardiomyocytes. Front. Mol. Biosci. 9, 879522 (2022).","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"44492_CR21","doi-asserted-by":"publisher","first-page":"12681","DOI":"10.1038\/s41598-022-16763-6","volume":"12","author":"MA Campeau","year":"2022","unstructured":"Campeau, M. A. & Leask, R. L. Empagliflozin mitigates endothelial inflammation and attenuates endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption. Sci. Rep. 12 (1), 12681 (2022).","journal-title":"Sci. Rep."},{"issue":"1","key":"44492_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jacbts.2024.08.003","volume":"10","author":"PE Nikolaou","year":"2025","unstructured":"Nikolaou, P. E. et al. Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage. JACC Basic. Transl Sci. 10 (1), 43\u201361 (2025).","journal-title":"JACC Basic. Transl Sci."},{"issue":"4","key":"44492_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00125-020-05359-2","volume":"64","author":"AA Sayour","year":"2021","unstructured":"Sayour, A. A. et al. Sodium\u2013glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia\u2013reperfusion injury: a meta-analysis. Diabetologia 64 (4), 737\u2013748 (2021).","journal-title":"Diabetologia"},{"key":"44492_CR24","first-page":"S359","volume":"135","author":"M Benedikt","year":"2023","unstructured":"Benedikt, M. et al. Impact of the SGLT2-inhibitor Empagliflozin on inflammatory biomarkers in acute myocardial infarction-a post-hoc analysis of the EMMY trial. Wien Klin. Wochenschr. 135, S359\u2013S360 (2023).","journal-title":"Wien Klin. Wochenschr"},{"issue":"1","key":"44492_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13098-022-00951-5","volume":"14","author":"S Gohari","year":"2022","unstructured":"Gohari, S. et al. The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial. Diabetol. Metab. Syndr. 14 (1), 170 (2022).","journal-title":"Diabetol. Metab. Syndr."},{"issue":"1","key":"44492_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","volume":"21","author":"P Paolisso","year":"2022","unstructured":"Paolisso, P. et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc. Diabetol. 21 (1), 77 (2022).","journal-title":"Cardiovasc. Diabetol."},{"key":"44492_CR27","doi-asserted-by":"publisher","first-page":"120178","DOI":"10.1016\/j.jep.2025.120178","volume":"352","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. Huoluo Xiaoling Pellet improves ischemic stroke by regulating metabolic disorders through integrins and ICAM1. J. Ethnopharmacol. 352, 120178 (2025).","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"44492_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12933-025-02777-7","volume":"24","author":"TT Yoo","year":"2025","unstructured":"Yoo, T. T. et al. Impact of sodium\u2013glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. Cardiovasc. Diabetol. 24 (1), 227 (2025).","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44492-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44492-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44492-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:01:57Z","timestamp":1784113317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44492-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44492"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44492-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients before they participated in the study. The study protocol was approved by the Ethics Committee of the National Institute for Medical Research Development (NIMAD) and the Institutional Review Board of the National Institute for Medical Research Development (Ethic Number: IR.NIMAD.REC.1400.160, IRCT number: IRCT20220521054950N1).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22105"}}